Publications by authors named "Olle Linder"

Claim this Profile
O
Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry.
Göran Wålinder, Jan Samuelsson, Per Näsman, Markus Hansson, Gunnar Juliusson, Olle Linder

Eur J Haematol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine Measurements for Diagnosing and Characterizing Leukemoid Reactions and Immunohistochemical Validation of a Granulocyte Colony-Stimulating Factor and CXCL8-Producing Renal Cell Carcinoma.
Maria Åström, Walid Tajeddinn, Mats G Karlsson, Olle Linder, Jan Palmblad

Biomark Insights· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.
Cecilie Hveding Blimark, Ingemar Turesson, Anna Genell, Lucia Ahlberg, Bo Björkstrand, Olle Linder

Haematologica· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.
Hareth Nahi, Anna Genell, Göran Wålinder, Katarina Uttervall, Gunnar Juliusson, Olle Linder

Eur J Haematol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.
Christen Lykkegaard Andersen, Mads Emil Bjørn, Mary Frances McMullin, Claire Harrison, Jan Samuelsson, Olle Linder

Leuk Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
Christen L Andersen, Mary F McMullin, Elisabeth Ejerblad, Sonja Zweegman, Claire Harrison, Olle Linder

Br J Haematol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
Martin Hjorth, Øyvind Hjertner, Lene Meldgaard Knudsen, Nina Gulbrandsen, Erik Holmberg, Olle Linder

Eur J Haematol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Lars Möllgård, Leonie Saft, Marianne Bach Treppendahl, Ingunn Dybedal, Jan Maxwell Nørgaard, Olle Linder

Haematologica· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
Magnus Björkholm, Asa R Derolf, Malin Hultcrantz, Sigurdur Y Kristinsson, Charlotta Ekstrand, Olle Linder

J Clin Oncol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Peter Gimsing, Kristina Carlson, Ingemar Turesson, Peter Fayers, Anders Waage, Olle Linder

Lancet Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Anders Waage, Peter Gimsing, Peter Fayers, Niels Abildgaard, Lucia Ahlberg, Olle Linder

Blood· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Michael Grövdal, Mohsen Karimi, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Olle Linder

Br J Haematol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome.
Michael Grövdal, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jan Astermark, Olle Linder

Clin Cancer Res· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
Christina Löfgren, Sören Lehmann, Kerstin Jönsson-Videsäter, Lars Möllgård, Olle Linder

Ther Drug Monit· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.
Stig Lenhoff, Martin Hjorth, Ingemar Turesson, Jan Westin, Peter Gimsing, Olle Linder

Haematologica· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.
Ulla Olsson-Strömberg, Martin Höglund, Magnus Björkholm, Inger Braide, Karin Carlson, Olle Linder

Leuk Lymphoma· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.
Jan Samuelsson, Hans Hasselbalch, Oystein Bruserud, Snezana Temerinac, Yvonne Brandberg, Olle Linder

Cancer· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
Stig Lenhoff, Martin Hjorth, Jan Westin, Lorentz Brinch, Bengt Bäckström, Olle Linder

Br J Haematol· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up.
Bengt Simonsson, Gunnar Oberg, Mats Bjoreman, Magnus Bjorkholm, Jan Carneskog, Olle Linder

Acta Haematol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival.
Ulla Olsson-Strömberg, Bengt Simonsson, Tomas Ahlgren, Magnus Björkholm, Karin Carlsson, Olle Linder

Hematol J· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III.
Jeanette Lundin, Anders Osterborg, Magnus Björkholm, Bo Björkstrand, Fredrik Celsing, Olle Linder

Hematol J· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired hemophilia masked by warfarin therapy: report on two cases.
Bertil Uggla, Olle Linder, Sam Schulman

Blood Coagul Fibrinolysis· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
Eva Hellström-Lindberg, Nina Gulbrandsen, Greger Lindberg, Tomas Ahlgren, Inger Marie S Dahl, Olle Linder

Br J Haematol· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia.
Helene Hallböök, Bengt Simonsson, Thomas Ahlgren, Magnus Björkholm, Jan Carneskog, Olle Linder, Mats Linderholm

Br J Haematol· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
Ulla Axdorph, Leif Stenke, Gunnar Grimfors, Jan Carneskog, Jan Hansen, Olle Linder

Br J Haematol· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis